

18-02 508-E

February 15 2018

US Securities & Exchange Commission
Office of FOIA and Privacy Act Operations
100 F Street, NE Mail Stop 5100
Washington, DC 20549-5100



Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit 10.1 to the form 8-K filed by SYNTA PHARMACEUTICALS CORP on July 21, 2011

In the event confidential treatment has not expired provide the specific date for which

confidential treatment is still in effect. I do not need a copy of the order. We authorize up to

\$61.00 in processing fees. Thank You,

Paul D'Souza
Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ
Phone: +44-2074334789
paul.dsouza@clarivate.com



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
STATION PLACE
100 F STREET, NE
WASHINGTON, DC 20549-2465

Office of FOIA Services

March 9, 2018

Mr. Paul D'Souza
Clarivate Analytics
160 Blackfriars Road
London, UK SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552
Request No. 18-02508-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on February 15, 2018, for Exhibit 10.1 to the Form 8-K filed by Synta Pharmaceuticals Corp. on July 21, 2011.

The search for responsive records has resulted in the retrieval of five pages of records that may be responsive to your request. They are being provided to you with this letter.

If you have any questions, please contact me at jacksonw@sec.gov or (202) 551-8312. You may also contact me at foiapa@sec.gov or (202) 551-7900. You also have the right to seek assistance from Jeffery Ovall as a FOIA Public Liaison or contact the Office of Government Information Services (OGIS) for dispute resolution services. OGIS can be reached at 1-877-684-6448 or Archives.gov or via e-mail at ogis@nara.gov.

Sincerely,

A handwritten signature in cursive script that reads "Warren E. Jackson".

Warren E. Jackson
FOIA Research Specialist

Enclosure

RECEIVED
JUL 22 2011
OFFICE OF THE SECRETARY

THIRD AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT

This Third Amendment (the "Third Amendment") executed on July 15, 2011 and is made and effective as of June 30, 2011 (the "Third Amendment Effective Date") and amends the Collaboration and License Agreement dated as of December 23, 2008 (as previously amended), between SYNTA PHARMACEUTICALS CORP., a Delaware corporation having a principal office at 45 Hartwell Avenue, Lexington, MA 02421, U.S.A. ("SYNTA"), and F. HOFFMANN-LA ROCHE LTD, a Swiss corporation having a principal office located at Grenzacherstrasse 124, CH-4070 Basel, Switzerland ("ROCHE BASEL") and HOFFMANN-LA ROCHE INC., a New Jersey corporation having a principal office at 340 Kingsland Street, Nutley, New Jersey 07110, U.S.A. ("ROCHE NUTLEY"; ROCHE BASEL and ROCHE NUTLEY together referred to as "ROCHE") (the "Agreement"). Capitalized terms shall have the meaning set forth in the Agreement.

INTRODUCTION

WHEREAS, SYNTA and ROCHE have reached agreement with respect to ROCHE having the right to continue Research related to Licensed Compounds; and

WHEREAS, the Parties wish to amend the Agreement, as described herein.

NOW THEREFORE, for and in consideration of the mutual covenants contained in this Third Amendment, the Parties agree:

1. Research License. SYNTA hereby grants to ROCHE for the period beginning on the Third Amendment Effective Date and continuing for the remainder of the Term, an exclusive, worldwide, paid-up right and license, without the right to grant sublicenses (except in accordance with Section 6.4), under the SYNTA Intellectual Property to enable ROCHE to perform Research relating to Licensed Compounds. As of the Third Amendment Effective Date, the compounds identified in Appendix A are deemed to be a complete list of Licensed Compounds. For clarity this list does not include Licensed Compounds returned to Synta as part of the Second Amendment executed on January 31, 2011.


2. Effect on Agreement. Except as amended by this Third Amendment, the Agreement shall remain in full force and effect. After the date of this Third Amendment, every reference in the Agreement to the "Agreement" shall mean the Agreement as amended by the Amendment, the First Amendment, the Second Amendment, and this Third Amendment.

[Remainder of page intentionally left blank.]


CONFIDENTIAL

IN WITNESS WHEREOF, the Parties have entered into this Amendment as of the Amendment Execution Date.

SYNTA PHARMACEUTICALS CORP.


By: 
Name: Mark Ehrlich
Title: CFO


F. HOFFMANN-LA ROCHE LTD

By: 
Name: Christophe Carissimo
Title: Global Licensing Director

By: 
Name: Dr. Melanie Frey Wick
Title: Vice Director

HOFFMANN-LA ROCHE INC.

By: 
Name: Joseph S. McCracken
Title: Vice President

Apprv'd As To Form
LAW DEPT.
By: 

CONFIDENTIAL

APPENDIX A












Licensed Compounds

CONFIDENTIAL










Compounds in Stage 2B or Later - Returned Compounds Removed

4-Feb-2011

Updated Jun 29, 2011

STA-12-5775/5837	RO5472959-000/001	
STA-12-6239	RO5508452-000	
STA-12-2614	RO5455962-000	
STA-12-2436	RO5529335-000	
STA-12-3934	RO5529336-000	
STA-12-6614	RO5524479-000	
STA-12-7198	RO5542090-000	
STA-12-7115	RO5536445-000	
STA-12-7281	RO5544727-000	
STA-12-7128	RO5537465-000	
STA-12-7526	RO5554020-000	

CONFIDENTIAL

STA-12-7527	RO5554021-000	
STA-71-1320	RO5520189-000	
STA-71-1563	RO5542885-000	
STA-12-7222	RO5542094-000	
STA-71-1727	RO5554304-000	
STA-71-1605	RO5545944-000	
STA-71-1699	RO5553329-000	
STA-12-7699	RO6603017-000	
STA-12-7750	RO6603022-000	
STA-71-1846	RO6800021-000	